Title:
USE OF ANTIBODY IN ANTI-TUMOR TREATMENT
Document Type and Number:
WIPO Patent Application WO/2022/218383
Kind Code:
A1
Abstract:
The present invention relates to a bispecific antibody against CTLA4 and PD-1, wherein the antibody is used for treating tumors, is administered in combination with an anti-VEGFR2 monoclonal antibody or an anti-VEGF monoclonal antibody, and comprises a first protein functional region targeting PD-1 and a second protein functional region targeting CTLA4, the first protein functional region being an immunoglobulin and the second protein functional region being a single-chain antibody, or the first protein functional region being a single-chain antibody and the second protein functional region being an immunoglobulin.
Inventors:
XIA YU (CN)
WANG ZHONGMIN MAXWELL (CN)
LI BAIYONG (CN)
WANG ZHONGMIN MAXWELL (CN)
LI BAIYONG (CN)
Application Number:
PCT/CN2022/086870
Publication Date:
October 20, 2022
Filing Date:
April 14, 2022
Export Citation:
Assignee:
AKESO PHARMACEUTICALS INC (CN)
AD PHARMACEUTICALS CO LTD (CN)
AD PHARMACEUTICALS CO LTD (CN)
International Classes:
C07K16/46; A61K39/395; A61K45/00; A61P35/00; A61P35/02; C12N15/13; G01N33/68
Domestic Patent References:
| WO2019179421A1 | 2019-09-26 | |||
| WO2020185722A2 | 2020-09-17 |
Foreign References:
| CN112300286A | 2021-02-02 | |||
| CN106967172A | 2017-07-21 | |||
| CN106188296A | 2016-12-07 | |||
| CN104974253A | 2015-10-14 | |||
| CN106967172A | 2017-07-21 | |||
| CN201610573836A | 2016-07-19 |
Other References:
SONG LEI, ZHOU RENGUI, LI XIANGYONG, PAN DEJIAN: "Combination of bevacizumab and dual immunotherapy for extensive-disease small-cell lung cancer: a case report", IMMUNOTHERAPY, vol. 13, no. 16, 1 November 2021 (2021-11-01), GB , pages 1309 - 1315, XP055976804, ISSN: 1750-743X, DOI: 10.2217/imt-2021-0025
WORLD HEALTH ORGANIZATION: "cadonilimabum", WHO DRUG INFORMATION, vol. 34, no. 4, 31 December 2020 (2020-12-31), CH , pages 947 - 949, XP009540392, ISSN: 1010-9609
TOPALIAN ET AL., N ENGL J MED, vol. 366, 2012, pages 2443 - 54
LIN ET AL., PNAS, vol. 105, 2008, pages 3011 - 3016
FREEMAN ET AL., J EXP MED, vol. 192, 2000, pages 1027 - 34
LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 8
CARTER ET AL., EUR J IMMUNOL, vol. 32, 2002, pages 634 - 43
FIFE ET AL., NATURE IMMUNOLOGY, vol. 10, 2011, pages 1185 - 1193
HOFMEYER ET AL., JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2011, pages 1 - 9
ARMANATH ET AL., SCIENCE TRANSMED, vol. 3, 2011, pages 1 - 13
FRANCISCO ET AL., J.EXP.MED., vol. 206, 2009, pages 3015 - 3029
LATCHMAN ET AL., PNAS, vol. 101, 2004, pages 10691 - 10696
IWAI ET AL., PNAS, vol. 99, 2002, pages 12293 - 12297
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", vol. 1-3, 1991, NIH PUBLICATION
ACIERNO ET AL.: "Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies", J MOL BIOL., vol. 374, no. 1, 2007, pages 130 - 46, XP022310713, DOI: 10.1016/j.jmb.2007.09.005
WHO DRUG INFORMATION, vol. 34, no. 4, 2020, pages 947 - 949
WORLD HEALTH ORGANIZATION: "cadonilimabum", WHO DRUG INFORMATION, vol. 34, no. 4, 31 December 2020 (2020-12-31), CH , pages 947 - 949, XP009540392, ISSN: 1010-9609
TOPALIAN ET AL., N ENGL J MED, vol. 366, 2012, pages 2443 - 54
LIN ET AL., PNAS, vol. 105, 2008, pages 3011 - 3016
FREEMAN ET AL., J EXP MED, vol. 192, 2000, pages 1027 - 34
LATCHMAN ET AL., NAT IMMUNOL, vol. 2, 2001, pages 261 - 8
CARTER ET AL., EUR J IMMUNOL, vol. 32, 2002, pages 634 - 43
FIFE ET AL., NATURE IMMUNOLOGY, vol. 10, 2011, pages 1185 - 1193
HOFMEYER ET AL., JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2011, pages 1 - 9
ARMANATH ET AL., SCIENCE TRANSMED, vol. 3, 2011, pages 1 - 13
FRANCISCO ET AL., J.EXP.MED., vol. 206, 2009, pages 3015 - 3029
LATCHMAN ET AL., PNAS, vol. 101, 2004, pages 10691 - 10696
IWAI ET AL., PNAS, vol. 99, 2002, pages 12293 - 12297
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", vol. 1-3, 1991, NIH PUBLICATION
ACIERNO ET AL.: "Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies", J MOL BIOL., vol. 374, no. 1, 2007, pages 130 - 46, XP022310713, DOI: 10.1016/j.jmb.2007.09.005
WHO DRUG INFORMATION, vol. 34, no. 4, 2020, pages 947 - 949
Attorney, Agent or Firm:
BEIJING C&S LAW FIRM (CN)
Download PDF:
Previous Patent: DEUTERATED PHENOL DERIVATIVES, PREPARATION METHOD THEREFOR, AND USE THEREOF
Next Patent: ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF
Next Patent: ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF